Low doses of insulin-like growth factor I improve insulin resistance, lipid metabolism, and oxidative damage in aging rats
The economics tell the story: 44% of Americans struggle to afford healthcare
In vivo, overexpression of Igfbp2 has been demonstrated to reduce bone mass and inhibit growth hormone (GH)-stimulated linear growth in GH transgenic mice, possibly by antagonizing the GH/IGF-I axis
Its signaling complexity (triple agonism) imposes heightened methodological vigilance: systematic glycemic monitoring to detect any paradoxical hyperglycemia linked to the glucagon arm, regular hepatic panel given the lipolytic effect, and lean mass tracking to quantify the share of weight loss linked to muscle depletion under severe caloric restriction
Sci Rep 12(1):21658 Akira S, Takeda K (2004) Toll-like receptor signalling
Effectiveness of weight management interventions for adults delivered in primary care: systematic review and meta-analysis of randomised controlled trials